1987
DOI: 10.1007/bf00326777
|View full text |Cite
|
Sign up to set email alerts
|

Conservative therapy of frequency, urgency and urge incontinence: A double-blind clinical trial of flavoxate hydrochloride, exybutinin chloride, emepronium bromide and placebo

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
12
0
4

Year Published

1991
1991
2023
2023

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 61 publications
(17 citation statements)
references
References 20 publications
1
12
0
4
Order By: Relevance
“…Owing to antispasmodic and anticholinergic properties, in addition to analgesic and local anesthetic effects, objective improvement of urody namic parameters has been demonstrated in neurogenic bladders [1-3, 17]. In accordance, subjective improve ment is unanimously reported in urge incontinence, al though significant changes in objective urodynamic vari ables remain controversial [14,[18][19][20]. Objective param eters specifying the quality of treatment response in en uresis are still lacking.…”
Section: Methodsmentioning
confidence: 79%
“…Owing to antispasmodic and anticholinergic properties, in addition to analgesic and local anesthetic effects, objective improvement of urody namic parameters has been demonstrated in neurogenic bladders [1-3, 17]. In accordance, subjective improve ment is unanimously reported in urge incontinence, al though significant changes in objective urodynamic vari ables remain controversial [14,[18][19][20]. Objective param eters specifying the quality of treatment response in en uresis are still lacking.…”
Section: Methodsmentioning
confidence: 79%
“…For instance, the efficacy of flavoxate and emepronium bromide has been doubted because objective param eters show no difference from placebo [14,15]. Propan theline, methantheline and oxybutynin seem to be supe rior in efficacy when compared to placebo [8], but the incidence and severity of side-effects are reported to be rather high.…”
Section: Discussionmentioning
confidence: 99%
“…Three articles [19][20][21] not specifying adverse events, one article [22] not differentiating adverse events between antimuscarinic and placebo, six articles [23][24][25][26][27][28] not discriminating adverse events between different fixed dosages, and three articles [29][30][31] only comparing different releases within the same antimuscarinic and dosage were excluded. Thus, we finally included 69 trials including one report [66] with two different age strata ( Table 2, Data S2).…”
Section: Resultsmentioning
confidence: 99%